cbdMD Achieves Key Milestone in UK Novel Food Regulatory Approval

Core Insights - cbdMD has achieved a significant milestone in the UK by advancing its Novel Food dossier (RP793) to the final phase of regulatory assessment with the UK Food Standards Agency (FSA), indicating a strong commitment to safety and quality in the CBD market [1][5] - The FSA's safety assessment confirms that cbdMD's proprietary CBD isolate meets UK food safety standards, paving the way for full authorization as a Novel Food [3][6] - The UK CBD market is projected to be worth £800 million in 2025, highlighting the growth potential for compliant CBD products [7] Regulatory Progress - cbdMD initiated the regulatory process in March 2021, submitting a comprehensive dossier that includes details on ingredient identity, quality, stability, and safety data [2] - In February 2022, cbdMD became the first U.S. brand to receive dossier validation from the FSA, demonstrating proactive engagement with regulatory authorities [2] - The FSA's safety assessment, published on February 28, 2025, confirms the high purity (>97%) of cbdMD's CBD isolate and its compliance with UK food safety regulations [3][6] Market Position and Consumer Confidence - cbdMD is positioned as a trusted brand in the CBD market, with a focus on providing safe and rigorously tested products [1][5] - The company is among the few legally authorized suppliers of CBD products in the UK, which is expected to enhance consumer awareness and drive sales [5] - The CEO of cbdMD emphasized that obtaining FSA approval will lead to greater consumer confidence and an expanded market share as demand for regulated CBD products rises [7]